Bioxytran, Inc.
BIXT
$0.03
$0.000.00%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.71M | 605.30K | 496.00K | 124.50K | 165.60K |
| Depreciation & Amortization | 2.10K | 2.90K | 4.20K | 2.50K | 1.90K |
| Other Operating Expenses | -- | -- | -- | -3.00K | -- |
| Total Operating Expenses | 1.94M | 610.20K | 500.20K | 226.60K | 517.00K |
| Operating Income | -1.94M | -610.20K | -500.20K | -226.60K | -517.00K |
| Income Before Tax | -2.07M | -522.20K | -282.70K | 35.40K | -1.35M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.07M | -522.20K | -282.70K | 35.40K | -1.35M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.07M | -522.20K | -282.70K | 35.40K | -1.35M |
| EBIT | -1.94M | -610.20K | -500.20K | -226.60K | -517.00K |
| EBITDA | -1.93M | -607.30K | -496.00K | -224.10K | -515.10K |
| EPS Basic | -0.02 | -0.01 | 0.00 | 0.00 | -0.02 |
| Normalized Basic EPS | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 |
| EPS Diluted | -0.02 | -0.01 | 0.00 | 0.00 | -0.02 |
| Normalized Diluted EPS | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 112.28M | 100.55M | 88.99M | 88.84M | 88.84M |
| Average Diluted Shares Outstanding | 112.28M | 100.55M | 88.99M | 88.84M | 88.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |